Eribulin Mesylate Injection
Product Images NDC 39822-2080

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 39822-2080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xgen Pharmaceuticals Djb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Taiwan-vial-1mg_2ml (Taiwan Vial 1mg 2ml)

Label for Eribulin Mesylate Injection, a single-dose vial containing 1 mg/2 mL (0.5 mg/mL) sterile solution for intravenous use. The label includes storage instructions (20° to 25°C, with permissible excursions), warnings about cytotoxicity, and manufacturing details for XGen Pharmaceuticals DJB, Inc. and Formosa Laboratories, Inc. It also shows the NDC number 39822-2080-1.*

FDA Label Image

Taiwan-single-carton-1mg_2ml (Taiwan Single Carton 1mg 2ml)

Packaging label for Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) single-dose vial. The label indicates intravenous use and describes the product as a sterile solution with a caution for cytotoxicity. Labeler is XGen Pharmaceuticals DJB, Inc., with NDC 39822-2080-1. The label includes usage and storage instructions, manufacturer information, and features blue and white color accents.*

FDA Label Image

Figure 1 (Eribulin Fig1)

A survival curve chart comparing the proportion of patients alive over time in months for Eribulin Mesylate Injection versus a control group. The chart shows patient survival probabilities from 0 to 36 months, with sample sizes indicated for each group, illustrating the difference in survival outcomes between 508 patients receiving Eribulin Mesylate Injection and 254 control patients.*

FDA Label Image

Figure 2 (Eribulin Fig2)

A Kaplan-Meier survival curve comparing survival probability over time (in months) between patients treated with Eribulin Mesylate Injection and those treated with Dacarbazine. The chart includes a legend, survival probability on the y-axis, time in months on the x-axis, and numbers of subjects at risk listed below the graph for each treatment group.*

FDA Label Image

Structural Formula (Eribulin Structure)

Chemical structure of eribulin mesylate, showing the molecular arrangement of atoms including carbon, hydrogen, oxygen, nitrogen, and a methylsulfonate group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.